<DOC>
	<DOC>NCT01596530</DOC>
	<brief_summary>To compare the activity of AZD8931 against placebo on the cell markers in cancer tumours</brief_summary>
	<brief_title>Evaluation of Drug Activity in Women With Breast Cancer and no Previous Herceptin Treatment</brief_title>
	<detailed_description>A Randomised Double-Blind Placebo-controlled Multicentre Phase I Study to Assess the Biological Activity of AZD8931 in Patients with Early Breast Cancer who are Ineligible for Treatment with trastuzumab as defined by IHC status</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Females aged 18 or older Early stage breast cancer and planned surgery Ineligible for Trastuzumab (Herceptin) treatment as per local guidelines World health Organisation performance status of 0 to 1 Tumour size amenable to obtaining adequate biopsies pre dosing. Eligible for Trastuzumab (Herceptin) Treatment Known sensitivity to AZD8931, its excipients or drugs in its class; Including oral tyrosine kinase inhibitors History of eye conditions e.g. previous injury within 3 months or clinically significant eye disease Concurrent malignancy Unable to discontinue medication or herbal supplement known to inhibit CYP3A4 or CYP2D6</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Breast Neoplasm</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Breast Tumour</keyword>
	<keyword>Cancer of Breast</keyword>
	<keyword>Cancer of the Breast</keyword>
</DOC>